作为治疗靶点的癌症干细胞：当前的临床发展和未来展望。

IF 4 2区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

STEM CELLS Pub Date : 2024-03-14 DOI:10.1093/stmcls/sxad092

Alex Philchenkov, Anna Dubrovska

{"title":"作为治疗靶点的癌症干细胞：当前的临床发展和未来展望。","authors":"Alex Philchenkov, Anna Dubrovska","doi":"10.1093/stmcls/sxad092","DOIUrl":null,"url":null,"abstract":"The key role of cancer stem cells (CSCs) in tumor development and therapy resistance makes them essential biomarkers and therapeutic targets. Numerous agents targeting CSCs, either as monotherapy or as part of combination therapy, are currently being tested in clinical trials to treat solid tumors and hematologic malignancies. Data from ongoing and future clinical trials testing novel approaches to target tumor stemness-related biomarkers and pathways may pave the way for further clinical development of CSC-targeted treatments and CSC-guided selection of therapeutic regimens. In this concise review, we discuss recent progress in developing CSC-directed treatment approaches, focusing on clinical trials testing CSC-directed therapies. We also consider the further development of CSC-assay-guided patient stratification and treatment personalization.","PeriodicalId":231,"journal":{"name":"STEM CELLS","volume":" ","pages":"173-199"},"PeriodicalIF":4.0000,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cancer Stem Cells as a Therapeutic Target: Current Clinical Development and Future Prospective.\",\"authors\":\"Alex Philchenkov, Anna Dubrovska\",\"doi\":\"10.1093/stmcls/sxad092\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The key role of cancer stem cells (CSCs) in tumor development and therapy resistance makes them essential biomarkers and therapeutic targets. Numerous agents targeting CSCs, either as monotherapy or as part of combination therapy, are currently being tested in clinical trials to treat solid tumors and hematologic malignancies. Data from ongoing and future clinical trials testing novel approaches to target tumor stemness-related biomarkers and pathways may pave the way for further clinical development of CSC-targeted treatments and CSC-guided selection of therapeutic regimens. In this concise review, we discuss recent progress in developing CSC-directed treatment approaches, focusing on clinical trials testing CSC-directed therapies. We also consider the further development of CSC-assay-guided patient stratification and treatment personalization.\",\"PeriodicalId\":231,\"journal\":{\"name\":\"STEM CELLS\",\"volume\":\" \",\"pages\":\"173-199\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2024-03-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"STEM CELLS\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/stmcls/sxad092\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"STEM CELLS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/stmcls/sxad092","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

癌症干细胞（CSCs）在肿瘤发生发展和耐药性治疗中起着关键作用，因此成为重要的生物标志物和治疗靶点。目前，许多靶向CSCs的药物，无论是作为单一疗法还是作为联合疗法的一部分，都在治疗实体瘤和血液恶性肿瘤的临床试验中接受测试。正在进行的临床试验和其他临床试验中测试靶向肿瘤干细胞相关生物标志物和通路的新方法的数据，可能为进一步临床开发针对CSC的治疗方法和CSC指导下的治疗方案选择铺平道路。在这篇简明综述中，我们讨论了开发造血干细胞导向治疗方法的最新进展，重点关注测试造血干细胞导向疗法的临床试验。我们还考虑了在造血干细胞检测指导下对患者进行分层和个性化治疗的进一步发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Cancer Stem Cells as a Therapeutic Target: Current Clinical Development and Future Prospective.

The key role of cancer stem cells (CSCs) in tumor development and therapy resistance makes them essential biomarkers and therapeutic targets. Numerous agents targeting CSCs, either as monotherapy or as part of combination therapy, are currently being tested in clinical trials to treat solid tumors and hematologic malignancies. Data from ongoing and future clinical trials testing novel approaches to target tumor stemness-related biomarkers and pathways may pave the way for further clinical development of CSC-targeted treatments and CSC-guided selection of therapeutic regimens. In this concise review, we discuss recent progress in developing CSC-directed treatment approaches, focusing on clinical trials testing CSC-directed therapies. We also consider the further development of CSC-assay-guided patient stratification and treatment personalization.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

STEM CELLS 医学-生物工程与应用微生物

CiteScore

10.30

自引率

1.90%

发文量

104

审稿时长

3 months

期刊介绍： STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. STEM CELLS is read and written by clinical and basic scientists whose expertise encompasses the rapidly expanding fields of stem and progenitor cell biology. STEM CELLS covers: Cancer Stem Cells, Embryonic Stem Cells/Induced Pluripotent Stem (iPS) Cells, Regenerative Medicine, Stem Cell Technology: Epigenetics, Genomics, Proteomics, and Metabonomics, Tissue-Specific Stem Cells, Translational and Clinical Research.